SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA was delisted on the 22nd of June, 2015.
0 hedge funds and large institutions have $0 invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 130 closing their positions.
100% less funds holding
Funds holding: 130 → 0 (-130)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $3.89B → $0 (-$3.89B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 130
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.14B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$541M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$442M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$317M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$152M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$7K | -67 | Closed |
|
|
LTFS
127
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$3K | -34 | Closed |
|
|
LWM
128
LBA Wealth Management
Jacksonville,
Florida
| – | -$2K | -20 | Closed |
|
|
FNBT
129
FineMark National Bank & Trust
Fort Myers,
Florida
| – | -$1K | -11 | Closed |
|
|
ZB
130
Zions Bancorporation
Salt Lake City,
Utah
| – | -$1K | -7 | Closed |
|
GEVA Hedge Fund Activity: Q2 2015 in Review
0 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2015, worth a combined $0 — down 100% from $3.89B a quarter earlier.
Sellers outnumbered buyers: 130 funds closed out of GEVA and 0 opened new positions — a net loss of 130 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.14B sold.
- 0 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2015, down from 130 in Q1 2015.
- Funds reported $0 of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2015, down 100% quarter-over-quarter.
- 0 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2015 and 130 closed out, a net change of -130 holders.
- The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q2 2015 was Baker Bros. Advisors, an estimated $1.14B sold.
Based on aggregated 13F filings for Q2 2015.